Boston Business Journal

Moderna Reports RSV Vaccine for Older Adults Is 84% Effective

Moderna Inc. announced Tuesday that its vaccine for respiratory syncytial virus (RSV) in adults over 60 years old is 84% effective at preventing lower respiratory tract diseases.

Based on the results, the Cambridge company plans to submit the vaccine for approval by July at the latest.

More on this story from Boston Business Journal

Copyright Boston Business Journal
Contact Us